KALA BIO (KALA) Stock Price, News & Analysis

Company Overview

KALA BIO, Inc. is a clinical-stage biotechnology company focused on developing regenerative therapies for rare diseases. The company uses its secretome-based platform, which is designed to harness biologically active proteins, growth factors and other components released by human cells, to develop treatments intended to repair damaged tissue and address underlying disease mechanisms.

KALA BIO’s lead investigational product is KPI-012, an engineered human mesenchymal stem cell secretome being developed for persistent corneal epithelial defects (PCED) associated with limbal stem cell deficiency. PCED is a rare and potentially serious condition in which the cornea does not properly heal. KPI-012 is intended to support corneal healing through multiple biological pathways.

The company was formerly known as Kala Pharmaceuticals, Inc. and adopted the KALA BIO name as it shifted its focus toward regenerative medicine and rare diseases. Its operations are based in the United States, and its development programs are primarily directed toward ophthalmic conditions with significant unmet medical needs. KPI-012 remains an investigational therapy and has not been established as safe or effective for marketing purposes.

Key Stats

• Today's Range: $0.53 to $0.58
• 50-Day Range: $0.51 to $1.09
• 52-Week Range: $0.49 to $993.95
• Volume: 80,317 shs
• Average Volume: 753,847 shs
• Market Capitalization: $10.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $75.00
• Consensus Rating: Reduce

KALA BIO Stock Analysis - MarketRank™

KALA BIO scored higher than 30% of companies evaluated by MarketBeat, and ranked 705th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Reduce

Consensus Rating

KALA BIO has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

KALA BIO has a consensus price target of $75.00, representing about 13,814.7% upside from its current price of $0.54.

Amount of Analyst Coverage

KALA BIO has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of KALA BIO is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of KALA BIO is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

KALA BIO has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.13% of the float of KALA BIO has been sold short.

Short Interest Ratio / Days to Cover

KALA BIO has a short interest ratio ("days to cover") of 1.41, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in KALA BIO has recently increased by 57.94%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

KALA BIO does not currently pay a dividend.

Dividend Growth

KALA BIO does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for KALA BIO this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for KALA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added KALA BIO to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, KALA BIO insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.24% of the stock of KALA BIO is held by insiders.

Percentage Held by Institutions

24.61% of the stock of KALA BIO is held by institutions.

Company Calendar

• Last Earnings: 8/19/2026
• Today: 9/18/2026
• Next Earnings (Estimated): 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:KALA
• CIK: 1479419
• Web: www.kalarx.com
• Phone: (781) 996-5252
• Fax: 781-642-0399
• Employees: 6
• Year Founded: 2009

Price Target and Rating

• Average Price Target for KALA BIO: $75.00
• High Price Target: $75.00
• Low Price Target: $75.00
• Potential Upside/Downside: +13,814.7%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($31.96)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.98 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -222.35%
• Return on Assets: -70.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.88
• Quick Ratio: 6.88

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.56 per share
• Price / Book: 0.04

Miscellaneous

• Outstanding Shares: 19,340,000
• Free Float: 18,907,000
• Market Cap: $10.42 million
• Optionable: Not Optionable
• Beta: -2.28